#BEGIN_DRUGCARD DB00212

# AHFS_Codes:
Not Available

# ATC_Codes:
C09XA01

# Absorption:
Absorbed following oral administration.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
126222-34-2

# ChEBI_ID:
Not Available

# Chemical_Formula:
C33H50N4O6S

# Chemical_IUPAC_Name:
(2S)-2-[(2R)-2-benzyl-3-(2-methylpropane-2-sulfonyl)propanamido]-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-5-yl)propanamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Remikiren is an orally active, high specificity renin inhibitor.

# Dosage_Forms:
Not Available

# Drug_Category:
Antihypertensive Agents
Protease Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
8498974	Clozel JP, Fischli W: Discovery of remikiren as the first orally active renin inhibitor. Arzneimittelforschung. 1993 Feb;43(2A):260-2.
8730917	Richter WF, Whitby BR, Chou RC: Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals. Xenobiotica. 1996 Mar;26(3):243-54.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
-6.13

# Experimental_LogP_Hydrophobicity:
3.9

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Remikiren

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)/t25-,27+,28-,29+,30-/m0/s1

# InChI_Key:
InChIKey=UXIGZRQVLGFTOU-PUNKFERVSA-N

# Indication:
For the treatment of hypertension and heart failure

# KEGG_Compound_ID:
C07465

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
212

# Mechanism_Of_Action:
Several in vivo experiments have shown that remikiren is specific for renin and does not decrease arterial pressure by an unrelated mechanism.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
630.838

# Molecular_Weight_Mono:
630.345106042

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1BBS

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164774779

# Pharmacology:
Remikiren is an orally available renin inhibitor with an established blood pressure-lowering effect in patients with essential hypertension. No data are available on the renal effects of remikiren in humans. In patients with essential hypertension, a single oral dose of remikiren can induce a renal vasodilation, without affecting the GFR and despite a significant decrease in blood pressure. This systemic and renal hemodynamic response is more pronounced in case of a more activated renin-angiotensin system.

# Predicted_LogP_Hydrophobicity:
2.42

# Predicted_LogS:
-4.5

# Predicted_Water_Solubility:
2.13e-02 g/l

# Primary_Accession_No:
DB00212

# Protein_Binding:
83%

# PubChem_Compound_ID:
5462340

# PubChem_Substance_ID:
46507286

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00163

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)(C)S(=O)(=O)C[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1CCCCC1)[C@H](O)[C@H](O)C1CC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Ro 42-5892

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:10 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Remikiren

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein. Membrane. Associated to membranes via binding to ATP6AP2

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10583449	van Paassen P, Navis GJ, De Jong PE, De Zeeuw D: Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension. Eur J Clin Invest. 1999 Dec;29(12):1019-26.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
7769797	MacFadyen RJ, Jones CR, Doig JK, Birnbock H, Reid JL: Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans. J Cardiovasc Pharmacol. 1995 Mar;25(3):347-53.
7994817	Kiowski W, Beermann J, Rickenbacher P, Haemmerli R, Thomas M, Burkart F, Meinertz T: Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation. 1994 Dec;90(6):2748-56.
8206619	Hilgers KF, Fischli W, Veelken R, Mann JF: Vascular renin in the guinea pig. Suppression by the renin inhibitor remikiren. Hypertension. 1994 Jun;23(6 Pt 2):861-4.
8319997	Clozel JP, Fischli W: Comparative effects of three different potent renin inhibitors in primates. Hypertension. 1993 Jul;22(1):9-17.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
REN

# Drug_Target_1_GenBank_ID_Gene:
L00073

# Drug_Target_1_GenBank_ID_Protein:
190994

# Drug_Target_1_GeneCard_ID:
REN

# Drug_Target_1_Gene_Name:
REN

# Drug_Target_1_Gene_Sequence:
>1221 bp
ATGGATGGATGGAGAAGGATGCCTCGCTGGGGACTGCTGCTGCTGCTCTGGGGCTCCTGT
ACCTTTGGTCTCCCGACAGACACCACCACCTTTAAACGGATCTTCCTCAAGAGAATGCCC
TCAATCCGAGAAAGCCTGAAGGAACGAGGTGTGGACATGGCCAGGCTTGGTCCCGAGTGG
AGCCAACCCATGAAGAGGCTGACACTTGGCAACACCACCTCCTCCGTGATCCTCACCAAC
TACATGGACACCCAGTACTATGGCGAGATTGGCATCGGCACCCCACCCCAGACCTTCAAA
GTCGTCTTTGACACTGGTTCGTCCAATGTTTGGGTGCCCTCCTCCAAGTGCAGCCGTCTC
TACACTGCCTGTGTGTATCACAAGCTCTTCGATGCTTCGGATTCCTCCAGCTACAAGCAC
AATGGAACAGAACTCACCCTCCGCTATTCAACAGGGACAGTCAGTGGCTTTCTCAGCCAG
GACATCATCACCGTGGGTGGAATCACGGTGACACAGATGTTTGGAGAGGTCACGGAGATG
CCCGCCTTACCCTTCATGCTGGCCGAGTTTGATGGGGTTGTGGGCATGGGCTTCATTGAA
CAGGCCATTGGCAGGGTCACCCCTATCTTCGACAACATCATCTCCCAAGGGGTGCTAAAA
GAGGACGTCTTCTCTTTCTACTACAACAGAGATTCCGAGAATTCCCAATCGCTGGGAGGA
CAGATTGTGCTGGGAGGCAGCGACCCCCAGCATTACGAAGGGAATTTCCACTATATCAAC
CTCATCAAGACTGGTGTCTGGCAGATTCAAATGAAGGGGGTGTCTGTGGGGTCATCCACC
TTGCTCTGTGAAGACGGCTGCCTGGCATTGGTAGACACCGGTGCATCCTACATCTCAGGT
TCTACCAGCTCCATAGAGAAGCTCATGGAGGCCTTGGGAGCCAAGAAGAGGCTGTTTGAT
TATGTCGTGAAGTGTAACGAGGGCCCTACACTCCCCGACATCTCTTTCCACCTGGGAGGC
AAAGAATACACGCTCACCAGCGCGGACTATGTATTTCAGGAATCCTACAGTAGTAAAAAG
CTGTGCACACTGGCCATCCACGCCATGGATATCCCGCCACCCACTGGACCCACCTGGGCC
CTGGGGGCCACCTTCATCCGAAAGTTCTACACAGAGTTTGATCGGCGTAACAACCGCATT
GGCTTCGCCTTGGCCCGCTGA

# Drug_Target_1_General_Function:
Involved in aspartic-type endopeptidase activity

# Drug_Target_1_General_References:
12045255	Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002 Jun;109(11):1417-27.
1608447	Dhanaraj V, Dealwis CG, Frazao C, Badasso M, Sibanda BL, Tickle IJ, Cooper JB, Driessen HP, Newman M, Aguilar C, et al.: X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature. 1992 Jun 11;357(6378):466-72.
2016271	Ishizuka Y, Shoda A, Yoshida S, Kawamura Y, Haraguchi K, Murakami K: Isolation and characterization of recombinant human prorenin in Chinese hamster ovary cells. J Biochem (Tokyo). 1991 Jan;109(1):30-5.
2493678	Sielecki AR, Hayakawa K, Fujinaga M, Murphy ME, Fraser M, Muir AK, Carilli CT, Lewicki JA, Baxter JD, James MN: Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. Science. 1989 Mar 10;243(4896):1346-51.
2540188	Burt DW, Nakamura N, Kelley P, Dzau VJ: Identification of negative and positive regulatory elements in the human renin gene. J Biol Chem. 1989 May 5;264(13):7357-62.
3032746	Fukamizu A, Nishi K, Nishimatsu S, Miyazaki H, Hirose S, Murakami K: Human renin gene of renin-secreting tumor. Gene. 1986;49(1):139-45.
3516796	Soubrier F, Panthier JJ, Houot AM, Rougeon F, Corvol P: Segmental homology between the promoter region of the human renin gene and the mouse ren1 and ren2 promoter regions. Gene. 1986;41(1):85-92.
3530608	Morris BJ: New possibilities for intracellular renin and inactive renin now that the structure of the human renin gene has been elucidated. Clin Sci (Lond). 1986 Oct;71(4):345-55.
6138751	Soubrier F, Panthier JJ, Corvol P, Rougeon F: Molecular cloning and nucleotide sequence of a human renin cDNA fragment. Nucleic Acids Res. 1983 Oct 25;11(20):7181-90.
6324167	Imai T, Miyazaki H, Hirose S, Hori H, Hayashi T, Kageyama R, Ohkubo H, Nakanishi S, Murakami K: Cloning and sequence analysis of cDNA for human renin precursor. Proc Natl Acad Sci U S A. 1983 Dec;80(24):7405-9.
6391881	Hardman JA, Hort YJ, Catanzaro DF, Tellam JT, Baxter JD, Morris BJ, Shine J: Primary structure of the human renin gene. DNA. 1984 Dec;3(6):457-68.

# Drug_Target_1_HGNC_ID:
HGNC:9958

# Drug_Target_1_HPRD_ID:
01564

# Drug_Target_1_ID:
298

# Drug_Target_1_Locus:
1q32

# Drug_Target_1_Molecular_Weight:
45058

# Drug_Target_1_Name:
Renin

# Drug_Target_1_Number_of_Residues:
406

# Drug_Target_1_PDB_ID:
1BBS

# Drug_Target_1_Pathway:
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Cilazapril Pathway	SMP00147
Enalapril Pathway	SMP00148
Fosinopril Pathway	SMP00149
Lisinopril Pathway	SMP00150
Moexipril Pathway	SMP00151
Perindopril Pathway	SMP00152
Quinapril Pathway	SMP00153
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Trandolapril Pathway	SMP00157

# Drug_Target_1_Pfam_Domain_Function:
PF00026	Asp
PF07966	A1_Propeptide

# Drug_Target_1_Protein_Sequence:
>Renin precursor
MDGWRRMPRWGLLLLLWGSCTFGLPTDTTTFKRIFLKRMPSIRESLKERGVDMARLGPEW
SQPMKRLTLGNTTSSVILTNYMDTQYYGEIGIGTPPQTFKVVFDTGSSNVWVPSSKCSRL
YTACVYHKLFDASDSSSYKHNGTELTLRYSTGTVSGFLSQDIITVGGITVTQMFGEVTEM
PALPFMLAEFDGVVGMGFIEQAIGRVTPIFDNIISQGVLKEDVFSFYYNRDSENSQSLGG
QIVLGGSDPQHYEGNFHYINLIKTGVWQIQMKGVSVGSSTLLCEDGCLALVDTGASYISG
STSSIEKLMEALGAKKRLFDYVVKCNEGPTLPDISFHLGGKEYTLTSADYVFQESYSSKK
LCTLAIHAMDIPPPTGPTWALGATFIRKFYTEFDRRNNRIGFALAR

# Drug_Target_1_Reaction:
Cleavage of Leu! bond in angiotensinogen to generate angiotensin I

# Drug_Target_1_Signals:
1-23

# Drug_Target_1_Specific_Function:
Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney

# Drug_Target_1_SwissProt_ID:
P00797

# Drug_Target_1_SwissProt_Name:
RENI_HUMAN

# Drug_Target_1_Synonyms:
Angiotensinogenase
EC 3.4.23.15
Renin precursor

# Drug_Target_1_Theoretical_pI:
7.07

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00212
